Professional Marketing briefs

Doctors who use the Internet and other technologies to interact with pharma, biotech and medical device companies, has grown by 23% to 87% of the total US physician population since 2004 according to the results of a new study by Manhattan Research. According to the study, physicians would like to use more online conferences and professional online videos and show a significant interest in reading medical journals online.

Lilly announced that it will eliminate around 300 positions in its US diabetes, neuroscience and osteoporosis sales forces as it introduces a new sales model featuring smaller territories manned by a rep with greater therapeutic expertise. The new sales model will replace large territories with multiple sales partners. Part of Lilly's strategy is to help reps better connect with physicians and increase accountability.

Zogenix will co-promote Sumavel DosePro (sumatriptan injection) needle-free delivery system with Astellas Pharma US. Sumavel DosePro which received FDA approval in July 2009, is a first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, a treatment that provides migraine relief within 10 minutes for some patients.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.